Pediatric glioblastoma in the setting of constitutional mismatch-repair deficiency treated with upfront lomustine and nivolumab
Pediatr Blood Cancer
.
2024 Jan;71(1):e30757.
doi: 10.1002/pbc.30757.
Epub 2023 Oct 26.
Authors
Jessica Krugman
1
,
Krupesh Patel
1
2
,
Anna Cantor
3
,
Matija Snuderl
4
,
Benjamin Cooper
5
,
Elcin Zan
6
,
Ali Radmanesh
6
,
E Teresa Hidalgo
7
,
Theodore Nicolaides
1
Affiliations
1
Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders, NYU Langone Health, New York, New York, USA.
2
Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
3
Center for Human Genetics and Genomics, Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
4
Department of Pathology, NYU Langone Health, New York, New York, USA.
5
Department of Radiation Oncology, NYU Langone Health, New York, New York, USA.
6
Department of Radiology, NYU Langone Health, New York, New York, USA.
7
Division of Pediatric Neurosurgery, The Hassenfeld Children's Hospital at NYU Langone Health, New York, New York, USA.
PMID:
37881859
DOI:
10.1002/pbc.30757
No abstract available
Publication types
Editorial
MeSH terms
Brain Neoplasms* / drug therapy
Child
Colorectal Neoplasms*
Glioblastoma* / drug therapy
Humans
Lomustine
Neoplastic Syndromes, Hereditary
Nivolumab
Substances
Lomustine
Nivolumab
Supplementary concepts
Turcot syndrome